Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C

Chihiro Morishima, Timothy R. Morgan, James E. Everhart, Elizabeth C. Wright, Minjun C. Apodaca, David R. Gretch, Mitchell I. Shiffman, Gregory T. Everson, Karen L. Lindsay, William M. Lee, Anna S F Lok, Jules L. Dienstag, Marc G. Ghany, Teresa M. Curto

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

The Siemens VERSANT® transcription-mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive results from the same blood draw; six were positive on repeat testing. We report the follow-up on these 11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior interferon nonresponders with advanced hepatic fibrosis. Treatment was continued for 48 weeks if patients had undetectable HCV RNA by PCR at treatment week 20. Frozen serum samples from weeks 12,20, 24,48, and 72 were subsequently tested by TMA. Nine of the 11 patients returned for testing (median, 30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among 759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17% overall exhibited consistently positive results, and 21% exhibited inconsistently positive results. SVR was more likely if TMA was consistently negative than if consistently or inconsistently positive. With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001). Conclusion: In PCR-negative samples, positive TMA results may indicate the presence of low levels of HCV RNA. However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result.

Original languageEnglish (US)
Pages (from-to)1412-1419
Number of pages8
JournalHepatology
Volume48
Issue number5
DOIs
StatePublished - Nov 2008

Fingerprint

Chronic Hepatitis C
Polymerase Chain Reaction
Hepacivirus
RNA
Therapeutics
Antiviral Agents
Fibrosis
Ribavirin
DNA-Directed RNA Polymerases
Hepatitis C
Serum
Interferons
Liver

ASJC Scopus subject areas

  • Hepatology
  • Medicine(all)

Cite this

Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. / Morishima, Chihiro; Morgan, Timothy R.; Everhart, James E.; Wright, Elizabeth C.; Apodaca, Minjun C.; Gretch, David R.; Shiffman, Mitchell I.; Everson, Gregory T.; Lindsay, Karen L.; Lee, William M.; Lok, Anna S F; Dienstag, Jules L.; Ghany, Marc G.; Curto, Teresa M.

In: Hepatology, Vol. 48, No. 5, 11.2008, p. 1412-1419.

Research output: Contribution to journalArticle

Morishima, C, Morgan, TR, Everhart, JE, Wright, EC, Apodaca, MC, Gretch, DR, Shiffman, MI, Everson, GT, Lindsay, KL, Lee, WM, Lok, ASF, Dienstag, JL, Ghany, MG & Curto, TM 2008, 'Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C', Hepatology, vol. 48, no. 5, pp. 1412-1419. https://doi.org/10.1002/hep.22487
Morishima, Chihiro ; Morgan, Timothy R. ; Everhart, James E. ; Wright, Elizabeth C. ; Apodaca, Minjun C. ; Gretch, David R. ; Shiffman, Mitchell I. ; Everson, Gregory T. ; Lindsay, Karen L. ; Lee, William M. ; Lok, Anna S F ; Dienstag, Jules L. ; Ghany, Marc G. ; Curto, Teresa M. / Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C. In: Hepatology. 2008 ; Vol. 48, No. 5. pp. 1412-1419.
@article{e76f14fe47d74704a0afd0e4a582b693,
title = "Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C",
abstract = "The Siemens VERSANT{\circledR} transcription-mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive results from the same blood draw; six were positive on repeat testing. We report the follow-up on these 11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior interferon nonresponders with advanced hepatic fibrosis. Treatment was continued for 48 weeks if patients had undetectable HCV RNA by PCR at treatment week 20. Frozen serum samples from weeks 12,20, 24,48, and 72 were subsequently tested by TMA. Nine of the 11 patients returned for testing (median, 30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among 759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17{\%} overall exhibited consistently positive results, and 21{\%} exhibited inconsistently positive results. SVR was more likely if TMA was consistently negative than if consistently or inconsistently positive. With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001). Conclusion: In PCR-negative samples, positive TMA results may indicate the presence of low levels of HCV RNA. However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result.",
author = "Chihiro Morishima and Morgan, {Timothy R.} and Everhart, {James E.} and Wright, {Elizabeth C.} and Apodaca, {Minjun C.} and Gretch, {David R.} and Shiffman, {Mitchell I.} and Everson, {Gregory T.} and Lindsay, {Karen L.} and Lee, {William M.} and Lok, {Anna S F} and Dienstag, {Jules L.} and Ghany, {Marc G.} and Curto, {Teresa M.}",
year = "2008",
month = "11",
doi = "10.1002/hep.22487",
language = "English (US)",
volume = "48",
pages = "1412--1419",
journal = "Hepatology",
issn = "0270-9139",
publisher = "John Wiley and Sons Ltd",
number = "5",

}

TY - JOUR

T1 - Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C

AU - Morishima, Chihiro

AU - Morgan, Timothy R.

AU - Everhart, James E.

AU - Wright, Elizabeth C.

AU - Apodaca, Minjun C.

AU - Gretch, David R.

AU - Shiffman, Mitchell I.

AU - Everson, Gregory T.

AU - Lindsay, Karen L.

AU - Lee, William M.

AU - Lok, Anna S F

AU - Dienstag, Jules L.

AU - Ghany, Marc G.

AU - Curto, Teresa M.

PY - 2008/11

Y1 - 2008/11

N2 - The Siemens VERSANT® transcription-mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive results from the same blood draw; six were positive on repeat testing. We report the follow-up on these 11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior interferon nonresponders with advanced hepatic fibrosis. Treatment was continued for 48 weeks if patients had undetectable HCV RNA by PCR at treatment week 20. Frozen serum samples from weeks 12,20, 24,48, and 72 were subsequently tested by TMA. Nine of the 11 patients returned for testing (median, 30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among 759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17% overall exhibited consistently positive results, and 21% exhibited inconsistently positive results. SVR was more likely if TMA was consistently negative than if consistently or inconsistently positive. With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001). Conclusion: In PCR-negative samples, positive TMA results may indicate the presence of low levels of HCV RNA. However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result.

AB - The Siemens VERSANT® transcription-mediated amplification (TMA) assay is extremely sensitive for the detection of hepatitis C virus (HCV) RNA in serum. Eleven of 180 subjects in the Hepatitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial who achieved polymerase chain reaction (PCR)-defined sustained virological response (SVR) at week 72 also had TMA-positive results from the same blood draw; six were positive on repeat testing. We report the follow-up on these 11 patients, and the reproducibility of TMA test results from PCR-negative samples in relationship to antiviral treatment outcome. Peginterferon and ribavirin treatment was initiated in 1145 prior interferon nonresponders with advanced hepatic fibrosis. Treatment was continued for 48 weeks if patients had undetectable HCV RNA by PCR at treatment week 20. Frozen serum samples from weeks 12,20, 24,48, and 72 were subsequently tested by TMA. Nine of the 11 patients returned for testing (median, 30 months after the week 72 visit), and all had undetectable HCV RNA by TMA and PCR. Among 759 PCR-negative samples obtained during treatment that were tested twice by TMA, 17% overall exhibited consistently positive results, and 21% exhibited inconsistently positive results. SVR was more likely if TMA was consistently negative than if consistently or inconsistently positive. With continued treatment, patients with inconsistently positive TMA results were more likely to become TMA-negative than TMA-positive (P < 0.0001). Conclusion: In PCR-negative samples, positive TMA results may indicate the presence of low levels of HCV RNA. However, because patients with positive TMA results may achieve SVR, management decisions during therapy should not be based on a single positive TMA test result.

UR - http://www.scopus.com/inward/record.url?scp=56149095245&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56149095245&partnerID=8YFLogxK

U2 - 10.1002/hep.22487

DO - 10.1002/hep.22487

M3 - Article

C2 - 18816437

AN - SCOPUS:56149095245

VL - 48

SP - 1412

EP - 1419

JO - Hepatology

JF - Hepatology

SN - 0270-9139

IS - 5

ER -